Thursday May 25th 2017

[Factors associated to the work situation of patients with multiple sclerosis].

CONCLUSIONS. Many of the factors that determine job loss in a patient with multiple sclerosis can be identified in time to allow them to be modified or offset. The knowledge provided by the studies mentioned above makes it possible to detect patients who are at risk of losing their job so that interventions can be carried out with the aim of preventing such a situation from occurring. More particularly, the vulnerability profile includes high physical disability and fatigue, progressive development of the disease and the presence of cognitive impairment, among others. PMID: 24504880 [PubMed – in process] (Source: Revista de Neurologia)

View original article – 

[Factors associated to the work situation of patients with multiple sclerosis].

Leave a Comment

More from category

MS Study Alert: Share Your Thoughts About MS Research
MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS
Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS
First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows
Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint
Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]